Similar articles

• Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.

  Piatosa B, Grenda R, Prokurat S. Piatosa B, et al. Transplant Proc. 1993 Aug;25(4):2574. Transplant Proc. 1993. PMID: 8356675 Clinical Trial. No abstract available.
• FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis.

  Kliem V, Eberhard OK, Oldhafer K, Schlitt HJ, Behrend M, Schaumann D, Pichlmayr R, Koch KM, Brunkhorst R. Kliem V, et al. Transplant Proc. 1996 Dec;28(6):3166-8. Transplant Proc. 1996. PMID: 8962227 Clinical Trial. No abstract available.
• Pentoxifylline reduces the first-dose reactions following OKT3.

  Vincenti FG, Vasconcelos M, Birnbaum JL, Tomlanovich SJ, Amend WJ Jr, Melzer JS, Snyder JP. Vincenti FG, et al. Transplant Proc. 1993 Apr;25(2 Suppl 1):57-9. Transplant Proc. 1993. PMID: 8465428 Clinical Trial. No abstract available.
• [Muromonab CD3].

  Akioka Y, Hattori M, Ito K. Akioka Y, et al. Nihon Rinsho. 2005 May;63 Suppl 5:747-50. Nihon Rinsho. 2005. PMID: 15954439 Review. Japanese. No abstract available.
• OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).

  First MR, Schroeder TJ, Hariharan S. First MR, et al. Transplant Proc. 1993 Apr;25(2 Suppl 1):25-6. Transplant Proc. 1993. PMID: 8465417 Review. No abstract available.